Boyalife Investment Inc. has reported owning 45% of the shares of Cesca Therapeutics Inc (NASDAQ:KOOL) in a new 13D filing with the SEC, amounting to 58.82 million shares in total. The filing also reveals the details of a purchase agreement entered into between the two parties in early February, which allows Boyalife Investment to designate certain members to Cesca Therapeutics’ Board of Directors, among other things. The full details can be found in the embedded filing below.
You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Boyalife Investment Inc | 26,470,588 | 0 | 26,470,588 | 0 | 26,470,588 | 20.3% |
| Boyalife (Hong Kong) Ltd | 58,823,529 | 0 | 58,823,529 | 0 | 58,823,529 | 45.0% |
Page 1 of 67 SEC Filing
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE
13D
Under the Securities Exchange Act of
1934
CESCA
THERAPEUTICS inc.
(Name
of Issuer)
Common Stock, par value $0.001
(Title of Class of Securities)
157131103
(CUSIP Number)
Xiaochun Xu, PhD, MBA
c/o Boyalife Group, Ltd.
800 Jiefang Road East
Wuxi City, China 214002
Tel: (+86) 15190288800
(Name, Address and Telephone Number
of Person Authorized to
Receive Notices and Communications)
February 13, 2016
(Date of Event which Requires
Filing of this Statement)
If the filing person has previously filed a statement on Schedule
13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e),
240.13d-1(f) or 240.13d-1(g), check the following box. [_]
NOTE: Schedules filed in paper format shall include a signed
original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.
* The remainder of this cover page shall be filled out for a
reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment
containing information which would alter disclosures provided in a prior cover page.
The information required on the remainder of this cover page
shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”)
or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,
see the Notes).
